Drugs / Pembrolizumab/Quavonlimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04736706 | Apr 2021 → Feb 2026 overdue | clear cell renal carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pembrolizumab/Quavonlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04736706 ↗ |
| Action | Inhibit | “the cytotoxic T-lymphocyte-associated protein 4 inhibitor quavonlimab” PMID 37882432 ↗ Oct 2023 |
| Route | Intravenous | “administered Q6W via IV infusion” NCT04736706 ↗ |